Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the latest setbacks for the controversial platform trial, the results from ...
DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.
Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.
Hosted on MSN17d
Denali Therapeutics’ ALS therapy fails to meet primary endpoint in Phase II/III trialThe drug was investigated as part of the HEALEY ALS Platform trial. Its primary endpoints were to assess changes in disease severity over time using the ALS Functional Rating Scale-Revised ...
Jan. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B ...
Denali Therapeutics Inc. (NASDAQ:DNLI) recently reported results from its phase 2/3 HEALEY ALS Platform Trial using DNL343 for the treatment of patients with Amyotrophic Lateral Sclerosis [ALS].
This milestone is a pivotal step in enabling the commencement of a Phase 2/3 clinical trial within the HEALEY ALS Platform Trial framework. The FDA has a period of 30 days to review the IND ...
These research centers share data and collaborate on clinical trials. One such clinical trial is the HEALEY ALS Platform Trial, a multi-center, multi-regimen clinical trial evaluating the safety and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback